Structure Therapeutics Inc. (GPCR)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Raymond C. Stevens Ph.D. | CEO & Director | 890.38k | -- | 1964 |
| Mr. Jun S. Yoon | Co- Founder, CFO & Secretary | 627.64k | -- | 1978 |
| Dr. Yingli Ma Ph.D. | Chief Technology Officer | 497.58k | -- | 1974 |
| Dr. Xichen Lin Ph.D. | Chief Scientific Officer | -- | -- | 1974 |
| Mr. Tony Peng | Senior Vice President of Legal | -- | -- | -- |
| Mr. Bob Gatmaitan | Senior Vice President of People | -- | -- | -- |
| Dr. Hui Lei Ph.D. | Senior Vice President of Chemistry | -- | -- | -- |
| Dr. Fang Zhang Ph.D. | Executive VP & Head of Biology | -- | -- | -- |
| Ms. Lani Ibarra | Senior Vice President of Clinical Development Operations | -- | -- | -- |
| Dr. Xinglong Jiang Ph.D. | Senior Vice President of Preclinical Development | -- | -- | -- |
Structure Therapeutics Inc.
- Sector:?
- Healthcare
- Industry:? Biotechnology
- Full Time Employees:?
- 136
Description
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
June 3, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
May 31, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
May 24, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission